Internal Medicine - Issue 3/2021
Review Articles
138
Don't we forget about biological therapy of hypercholesterolemia with PCSK9-inhibitors?
Vladimír Soška, Ondřej Kyselák
143
150
Treatment strategies for myelodysplastic syndrome in 2021
Petra Bělohlávková
157
Therapy of 3 patients with Erdhiem-Chester disease with cladribin or cladribin in combination with cyclophosphamide. Case report and review of the therapy
Zdeněk Král, Zdeněk Řehák, Marta Krejčí, Renata Koukalová, Sabina Ševčíková, Luděk Pour, Martin Krejčí, Martin Štork, Viera Sandecká, Zdeněk Adam
165
Rivaroxaban for the treatment and prevention of reccurence of venous thromboembolism in children
Eliška Boženková, Miroslav Souček
Case reports
175
Pembrolizumab-induced hypothyreosis and subcutaneous bleeding
Pavel Polák, Jana Špeldová, Monika Bratová, Jiřina Zavřelová, Miroslav Penka
180
Vericiguat in patients with heart failure and reduced ejection fraction
Jindřich Špinar, Lenka Špinarová, Jiří Vítovec
184
Komentáře k analýze složení směsi flavonoidů v tabletách Diozen 500 mg metodou UHPLC
František Kováčik, Anna Šantorová
Internal Medicine
2021 Issue 3
Most read in this issue
- What's new in the 2020 update of the CEAP classification system of chronic venous disease?
- Vericiguat in patients with heart failure and reduced ejection fraction
- The use of moxonidine in the treatment of arterial hypertension
- Treatment strategies for myelodysplastic syndrome in 2021